Skeletal Senescence with Aging and Type 2 Diabetes

Area of Science:

• Gerontology
• Metabolic diseases
• Bone biology

Background:

• Osteoporosis and type 2 diabetes (T2D) frequently coexist, sharing links to poor bone quality and increased fracture risk.
• Shared fundamental mechanisms in aging and energy metabolism are implicated in both conditions.
• Cellular senescence, a state of irreversible cell cycle arrest, is increasingly recognized as a contributor to chronic diseases.

Purpose of the Study:

• To explore the role of cellular senescence in the pathogenesis of osteoporosis and T2D.
• To investigate the potential of targeting senescent cells as a therapeutic strategy for skeletal complications in T2D.

Main Methods:

• Review of accumulating evidence on cellular senescence in bone-resident cells.
• Examination of recent findings on T2D-induced senescence in osteocytes (in mouse models).

Main Results:

• Aging leads to increased cellular senescence in various bone-resident cell types.
• Type 2 diabetes (T2D) can induce premature senescence in osteocytes, even in young adulthood (as observed in mice).
• Therapeutic elimination of senescent cells has shown promise in mitigating age-related bone loss and T2D metabolic dysfunction.

Conclusions:

• Cellular senescence is a critical, shared mechanism in aging, osteoporosis, and type 2 diabetes (T2D).
• Senescent cells in bone are implicated in the skeletal fragility associated with T2D.
• Interventions targeting senescent cells warrant further investigation for treating skeletal complications in T2D, mirroring their efficacy in aging.